tiprankstipranks
In this article:
Blurbs

Analysts Offer Insights on Healthcare Companies: Vor Biopharma (VOR) and Cyclo Therapeutics (CYTH)

In this article:
In this article:

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Vor Biopharma (VORResearch Report) and Cyclo Therapeutics (CYTHResearch Report) with bullish sentiments.

Vor Biopharma (VOR)

B.Riley Financial analyst Justin Walsh reiterated a Buy rating on Vor Biopharma today and set a price target of $32.00. The company’s shares closed last Friday at $4.25.

According to TipRanks.com, Walsh ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -48.3% and a 13.2% success rate. Walsh covers the Healthcare sector, focusing on stocks such as Compass Therapeutics, Eton Pharmaceuticals, and Cytosorbents.

Currently, the analyst consensus on Vor Biopharma is a Strong Buy with an average price target of $23.83, implying a 441.6% upside from current levels. In a report released today, JMP Securities also reiterated a Buy rating on the stock with a $15.00 price target.

See today’s best-performing stocks on TipRanks >>

Cyclo Therapeutics (CYTH)

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Cyclo Therapeutics, with a price target of $10.00. The company’s shares closed last Friday at $2.09, close to its 52-week low of $1.88.

According to TipRanks.com, McCarthy ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -41.5% and a 7.9% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Brainstorm Cell Therapeutics, Brooklyn ImmunoTherapeutics, and SELLAS Life Sciences Group.

Cyclo Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $10.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on VOR:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed

In this article:

Latest News Feed